Diagnostics and Therapy for Malignant Tumors DOI Creative Commons
Chih‐Yang Tsai, Chunyu Wang,

Hasok Chang

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2659 - 2659

Published: Nov. 21, 2024

Malignant tumors remain one of the most significant global health challenges and contribute to high mortality rates across various cancer types. The complex nature these requires multifaceted diagnostic therapeutic approaches. This review explores current advancements in methods, including molecular imaging, biomarkers, liquid biopsies. It also delves into evolution strategies, surgery, chemotherapy, radiation therapy, novel targeted therapies such as immunotherapy gene therapy. Although progress has been made understanding biology, future oncology lies integration precision medicine, improved tools, personalized approaches that address tumor heterogeneity. aims provide a comprehensive overview state diagnostics treatments while highlighting emerging trends lie ahead.

Language: Английский

Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges DOI Creative Commons
Jeong Uk Lim, Junyang Jung, Yeon Wook Kim

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 470 - 470

Published: Feb. 14, 2025

Tyrosine kinase inhibitors (TKIs) have transformed the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. However, resistance remains a major challenge in clinical practice. The tumor microenvironment (TME) is complex system composed cells, immune and non-immune non-cellular components. Evidence indicates that dynamic changes TME during TKI are associated with development resistance. Research has focused on identifying how each component interacts tumors TKIs to understand therapeutic targets could address In this review, we describe components, such as fibroblasts, blood vessels, checkpoint proteins, cytokines, interact EGFR-mutant they can promote TKIs. Furthermore, discuss potential strategies targeting novel approach.

Language: Английский

Citations

1
Dysregulated Signalling Pathways Driving Anti-cancer Drug Resistance DOI Open Access

Nauf Bou Antoun,

Athina‐Myrto Chioni

Published: July 19, 2023

One of the leading causes death worldwide, in both man and woman, is cancer. Despite significant development therapeutic strategies, inevitable emergence drug resistance limits success impedes curative outcome. Intrinsic acquired are common mechanisms responsible for cancer relapse. Several factors crucially regulate tumourigenesis resistance, including physical barriers, tumour microenvironment (TME), heterogeneity, genetic epigenetic alterations, immune system, burden, growth kinetics undruggable targets. Moreover, transforming factor-beta (TGF-β), Notch, epidermal factor receptor (EGFR), integrin-extracellular matrix (ECM), nuclear kappa-light-chain-enhancer activated B cells (NF-κB), phosphoinositol-3-kinase/protein kinase B/mammalian target rapamycin (PI3K/Akt/mTOR), wingless-related integration site (Wnt)/β-catenin), Janus kinase/signal transducers activators transcription (JAK/STAT) RAS/RAF/mitogen-activated protein (MAPK) signalling pathways some key players that have a pivotal role mechanisms. To guide future treatments improve results, deeper comprehension necessary. This review will cover intrinsic give comprehensive overview recent research on enable to bypass barriers put by treatments, like “satellite navigation”, find alternative routes carry their “journey” progression.

Language: Английский

Citations

15
Wnt Pathway-Targeted Therapy in Gastrointestinal Cancers: Integrating Benchside Insights with Bedside Applications DOI Creative Commons
Ashok Kumar Nayak,

Hannah Streiff,

Iván González

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(3), P. 178 - 178

Published: Jan. 24, 2025

The Wnt signaling pathway is critical in the onset and progression of gastrointestinal (GI) cancers. Anomalies this pathway, often stemming from mutations components such as adenomatous polyposis coli (APC) or β-catenin, lead to uncontrolled cell proliferation survival. In case colorectal cancer, dysregulation drives tumor initiation growth. Similarly, aberrant contributes development, metastasis, resistance therapy other GI cancers, gastric, pancreatic, hepatocellular carcinomas. Targeting its downstream effectors has emerged a promising therapeutic strategy for combating these highly aggressive malignancies. Here, we review pathogenesis cancers further explore potential targeting various pathway. Furthermore, summarize integrate preclinical evidence supporting efficacy potent inhibitors with completed ongoing clinical trials Additionally, discuss challenges pathway-targeted therapies overcome concerns effective translation.

Language: Английский

Citations

0
Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research DOI Open Access

Nauf Bou Antoun,

Hiba-Tun-Noor A. Mahmood,

Anthony J. Walker

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 1799 - 1799

Published: Feb. 20, 2025

Primary or acquired resistance to therapeutic agents is a major obstacle in the treatment of cancer patients. Cervical fourth leading cause deaths among women worldwide and, despite advances screening and treatments, many patients with advanced stage cervical have high recurrence rate within two years standard treatment, drug being contributing factor. The development cell lines can facilitate comprehensive investigation mechanisms, which cannot be easily performed clinical trials. This study aimed create three novel robust (HeLa, CaSki, SiHa) fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor (PD173074). All drug-resistant (DR) overexpressed FGFR1, FGFR2, FGF2, FGF4, FGF7 proteins that were also localized nucleus. In addition, DR cells had significantly more aggressive phenotype (more migratory proliferative, less apoptotic) compared parental lines. These are critical tool for understanding molecular mechanisms underpinning identification potential biomarkers. Moreover, availability such may effective strategies using FGFR inhibitors combination other target pathways responsible inhibitors.

Language: Английский

Citations

0
Mapping molecular landscapes in triple-negative breast cancer: insights from spatial transcriptomics DOI
Fares Saeed H. Al-Mansour, Hassan H. Almasoudi, Ali Albarrati

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 22, 2025

Language: Английский

Citations

0
Integrins in Cancer Drug Resistance: Molecular Mechanisms and Clinical Implications DOI Open Access
Yoshinobu Kariya, Michiru Nishita

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3143 - 3143

Published: March 28, 2025

It is estimated that between 80 and 90% of mortality in cancer patients directly or indirectly related to drug resistance. Consequently, overcoming resistance represents a significant challenge the treatment cancer. Integrins are transmembrane adhesion molecules facilitate linkage extracellular matrix (ECM) cytoskeleton, thereby enabling activation various cellular signaling pathways. highly expressed cancers contribute progression through invasion metastasis. In addition, recent studies have revealed integrins play pivotal role development This review will first provide an overview integrin function classification. then discusses advances understanding how cancer, with focus on ECM, transporters, epithelial-to-mesenchymal transition (EMT), stemness, PD-L1, glycosylation. Finally, potential applications as targets for therapeutic agents against drug-resistant also summarized.

Language: Английский

Citations

0
Nanotechnology in cancer treatment: revolutionizing strategies against drug resistance DOI Creative Commons
Syed Mubashar Sabir, Ali Salman B. Thani, Qamar Abbas

et al.

Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 13

Published: April 30, 2025

A notable increase in cancer-related fatalities and morbidity worldwide is attributed to drug resistance. The factors contributing resistance include efflux via ABC transporters, apoptosis evasion, epigenetic alterations, DNA repair mechanisms, the tumor microenvironment, among others. Systemic toxicities associated with conventional cancer diagnostics therapies have led development of alternative approaches, such as nanotechnology, enhance diagnostic precision improve therapeutic outcomes. Nanomaterial, including carbon nanotubes, dendrimers, polymeric micelles, liposomes, shown significant benefits diagnosis treatment due their unique physicochemical properties, biocompatibility, stability, enhanced permeability, retention characteristics, targeted delivery. Building on these advantages, this review conducted through comprehensive analysis recent literature explore principal mechanisms resistance, potential nanomaterials revolutionize selective delivery treatment. Additionally, strategies employed by overcome tumors, pump inhibition, multidrug loading, gene silencing are discussed detail. Furthermore, we examine challenges that limit application impede transition clinical use.

Language: Английский

Citations

0
Targeting cell signaling pathway ALKBH5/Beclin1/ULK1 in lung cancer by 5-flurouracil- loaded P (AAm/SA) nanogel in rats DOI
Ahmad S. Kodous,

Eman Salah Eldin,

Hebatallah E. Mohamed

et al.

APOPTOSIS, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

Citations

0
Unveiling the Dynamic Interplay between Cancer Stem Cells and the Tumor Microenvironment in Melanoma: Implications for Novel Therapeutic Strategies DOI Open Access
Patrízia Limonta, Raffaella Chiaramonte, Lavinia Casati

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(16), P. 2861 - 2861

Published: Aug. 16, 2024

Cutaneous melanoma still represents a significant health burden worldwide, being responsible for the majority of skin cancer deaths. Key advances in therapeutic strategies have significantly improved patient outcomes; however, most patients experience drug resistance and tumor relapse. Cancer stem cells (CSCs) are small subpopulation different tumors, including melanoma, endowed with distinctive capacities self-renewal differentiation into bulk cells. Melanoma CSCs characterized by expression specific biomarkers intracellular pathways; moreover, they play pivotal role onset, progression resistance. In recent years, great efforts been made to dissect molecular mechanisms underlying protumor activities provide basis novel CSC-targeted therapies. Herein, we highlight intricate crosstalk between bystander microenvironment (TME), immune cells, endothelial cancer-associated fibroblasts (CAFs), its progression. Specifically, discuss peculiar escape host surveillance, recruit immunosuppressive educate toward an phenotype. We also address currently investigated that could pave way new promising approaches care.

Language: Английский

Citations

2
Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models DOI Open Access

Razia Aslam,

Cathy E. Richards, Joanna Fay

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(24), P. 13264 - 13264

Published: Dec. 10, 2024

The CDK4/6 inhibitor Ribociclib has shown limited efficacy as a monotherapy in colorectal cancer (CRC). However, combining with targeted therapies could present viable strategy for treating CRC. This study evaluated the combination of and PI3K Alpelisib across four distinct cell lines representing different mutational statuses (

Language: Английский

Citations

2